1. Introduction

The legal limits on exploitation of genetic materials concern the collection, possession, analysis, storage, transfer, patenting and commercial use of biological materials containing genetic information. These materials include human DNA, blood, tissues, cells, embryos, plant varieties, animal genetic resources, microorganisms and genetic samples obtained from Indigenous or local communities.

Genetic materials have significant scientific and commercial value. They may support pharmaceutical research, gene therapies, personalized medicine, agricultural biotechnology and the development of diagnostic tests. However, their exploitation raises fundamental questions about bodily autonomy, informed consent, privacy, ownership, intellectual property, discrimination and the fair distribution of commercial benefits.

The central legal principle is that scientific or commercial usefulness does not automatically authorize unrestricted exploitation of genetic materials. The applicable restrictions depend on the type and source of material, the purpose of its use, the consent obtained and the jurisdiction involved.

This explanation focuses on Indian law, supplemented by important international principles and comparative judicial decisions.

2. Meaning and scope of genetic-material exploitation

Exploitation means using genetic materials or genetic information to obtain scientific, medical, commercial or other benefits. It may be lawful, unlawful or ethically objectionable, depending on the circumstances.

Genetic Algorithms: From Theory to Application · SWAYAM Plus

Human genetic materials

Blood, tissue, cells, DNA samples, reproductive material and derived cell lines. Relevant issues include consent, privacy, medical confidentiality and commercialization.

Journey of a Seed to Asia's Largest Germplasm Bank----Chinese Academy of Sciences

Plant and animal genetic resources

Seeds, germplasm, breeding material and genetic resources used in agriculture, conservation and biotechnology. Access permits and benefit-sharing requirements may apply.

Ehec in Schleswig-Holstein: So schütze ich mich vor einer Infektion

Microbial and other biological resources

Bacteria, fungi and other biological materials used for enzymes, medicines, industrial processes and research, subject to applicable biosafety and biodiversity laws.

The law must distinguish between the physical biological sample, the genetic information derived from it, an invention developed through research, and a naturally occurring genetic sequence. Each may attract different legal protections.

3. Principal legal limits

A. Informed consent and bodily autonomy

A person’s biological material should not be collected or used for an undisclosed purpose where applicable law requires consent. Consent to medical treatment does not necessarily constitute consent to unrelated research, genetic testing, commercial licensing or indefinite storage.

A legally sound consent process should explain:

What material will be collected and what tests will be performed.

Whether the material or genetic information will be shared with third parties.

Whether commercial research or product development is contemplated.

Whether samples will be retained, reused or transferred internationally.

What privacy safeguards, withdrawal options and limitations apply.

Consent must satisfy the relevant legal standard and must not be obtained through deception, coercion or material nondisclosure.

Case law: Moore v. Regents of the University of California (1990), 51 Cal. 3d 120.

The California Supreme Court considered a patient's allegations that doctors had used his tissues to develop a commercially valuable cell line without adequately disclosing their research and financial interests. The court rejected his conversion claim based on ownership of the excised cells but allowed claims based on breach of fiduciary duty and lack of informed consent to proceed.

FindLaw+1

Legal significance: A researcher may not be free to conceal material conflicts of interest merely because the law does not recognize the donor as the owner of every subsequent cell line or invention.

B. Privacy and protection of genetic information

Genetic information can reveal sensitive facts about an individual, biological relatives and potentially future generations. Its collection and use may therefore engage privacy, confidentiality and data-protection obligations.

Potentially unlawful practices include:

Disclosing identifiable genetic test results without an appropriate legal basis.

Using samples for undisclosed purposes that require further authorization.

Sharing genetic information without adequate safeguards.

Using genetic information for prohibited discrimination or unauthorized profiling.

Indian constitutional framework: Article 21 of the Constitution protects life and personal liberty and has been interpreted to include privacy.

**Case law: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), (2017) 10 SCC 1.

The Supreme Court of India recognized privacy as a constitutionally protected fundamental right. Its reasoning is relevant to genetic information because control over intimate personal information and decisions affecting bodily autonomy may fall within privacy protections.

Legal significance: State collection or use of genetic information must satisfy applicable constitutional requirements, including legality and appropriate safeguards. Private-sector processing must also comply with the relevant statutory framework; constitutional privacy principles do not, by themselves, answer every private ownership or compensation dispute.

C. Ownership of biological samples and derived inventions

A central difficulty is determining whether a person retains ownership rights over material removed from their body and whether those rights extend to extracted DNA, cultured cells, genetic data or patented inventions.

Three questions must be separated:

Who lawfully controls the original sample?

Who may use the sample and information derived from it?

Who owns any patentable invention created through research?

These rights are not necessarily held by the same person.

In Moore, the California Supreme Court distinguished the patient's claims concerning his removed cells from rights in a developed and patented cell line. It declined to extend the tort of conversion to the excised cells, while recognizing potential liability for failures of disclosure and informed consent.

Justia Law+1

Legal significance: The case does not establish a universal rule that human tissues can never be property. It demonstrates that ownership, consent and duties of disclosure must be analyzed separately under the applicable jurisdiction's law.

D. Regulation of genetic-resource access in India

India regulates access to biological resources and associated traditional knowledge through the Biological Diversity Act, 2002, as amended in 2023, together with the applicable rules and regulations.

The legislation addresses access for research, bio-survey and commercial utilization, benefit claimers, and the interests of communities that conserve biological resources or hold associated traditional knowledge. Importantly, the 2023 amendments exclude human genetic material from the statutory definition of biological resources under this Act. Human genetic samples therefore require separate analysis under the applicable medical, privacy, research and other legal frameworks.

Indian Kanoon+2

Relevant legal controls may include:

Applicable approval, registration or intimation requirements for access to Indian biological resources.

Rules governing transfers of research material to foreign persons or entities.

Restrictions or procedures associated with intellectual-property applications involving regulated biological resources.

Benefit-sharing obligations where the statutory conditions apply.

Protection of associated traditional knowledge and the interests of qualifying benefit claimers.

The precise requirements depend on the person's status, the biological resource involved, the purpose of access and the current statutory provisions.

Case-law qualification: These statutory controls should not be confused with a general legal prohibition on exploiting every form of genetic material. The statutory exclusion of human genetic material is particularly important when determining whether the Biological Diversity Act applies to a particular dispute.

E. Commercial exploitation and benefit-sharing

Commercial exploitation becomes especially controversial when researchers or corporations derive substantial financial benefits from biological resources collected from particular communities or territories.

For example, a company might investigate a plant traditionally used by a local community, identify a useful biochemical compound, and develop a commercial product. The legal questions include whether access was lawful, whether traditional knowledge was used, whether permissions were required and whether benefits must be shared.

The Nagoya Protocol establishes an international framework for access to genetic resources and the fair and equitable sharing of benefits arising from their utilization.

Under Articles 5 and 6, the framework addresses benefit-sharing, prior informed consent where applicable, and mutually agreed terms. Article 7 addresses traditional knowledge associated with genetic resources held by Indigenous and local communities. Implementation depends on applicable domestic legislation.

Convention on Biological Diversity+1

Benefits may be monetary or non-monetary, including royalties, research collaboration, technology transfer, training or other agreed contributions.

Legal significance: Lawful access to a resource does not necessarily eliminate separate benefit-sharing duties. Equally, not every commercial use of a naturally occurring substance automatically creates a royalty entitlement for every person or community connected with it.

F. Patent protection and genetic discoveries

Patent law imposes an important limit on the monopolization of genetic materials. The discovery of a naturally occurring gene or biological property is not necessarily equivalent to inventing a patentable product or process.

In India, Section 3(c) of the Patents Act, 1970 excludes the discovery of a scientific principle or the formulation of an abstract theory, as well as the discovery of a living thing or non-living substance occurring in nature, from patentability.

Other exclusions may also be relevant, including Section 3(j), concerning plants and animals or parts thereof, subject to the statutory wording and exceptions.

Case law: Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).

The United States Supreme Court held that naturally occurring DNA does not become patent-eligible merely because it has been isolated. It distinguished complementary DNA (cDNA), which may be patent-eligible because it is not naturally occurring in the same form. The Court did not decide every question concerning altered genetic sequences, diagnostic methods or applications of genetic knowledge.

LII / Legal Information Institute+1

Legal significance for India: The decision is persuasive comparative authority, not binding Indian precedent. Indian patentability must be assessed under the Patents Act, 1970 and the relevant Indian judicial decisions.

G. Genetic discrimination and misuse

Genetic information may be used to predict susceptibility to disease, identify biological relationships or assess inherited characteristics. This creates risks when employers, insurers, educational institutions or commercial organizations use genetic information for decisions unrelated to a legitimate and lawful purpose.

Relevant legal questions include:

Whether the collection or processing of the information has a lawful basis.

Whether the person was adequately informed.

Whether confidentiality and security requirements were met.

Whether the use violates constitutional rights, applicable privacy law or sector-specific protections.

Whether the conduct amounts to fraud, unlawful discrimination or another actionable wrong under the relevant law.

In India, the Digital Personal Data Protection Act, 2023 may be relevant to digital genetic information when its scope and applicability requirements are satisfied. The applicable commencement notifications and rules must be checked for the particular date and obligation. Physical samples and information that fall outside a statute's definition or scope may require separate analysis.

The constitutional principles in Puttaswamy provide an important foundation for evaluating privacy intrusions, but the specific legal remedy depends on the facts and the applicable legislation.

H. Research ethics and secondary use

Genetic materials are frequently retained after the original medical procedure or research project. Subsequent use may involve new scientific questions, international collaboration, commercial development or sequencing technologies that were not contemplated when the material was first collected.

The principal concerns are:

Whether the original consent covers the proposed secondary use.

Whether fresh consent or ethics-committee review is required.

Whether the material can genuinely be treated as anonymized.

Whether data-sharing agreements adequately restrict unauthorized use.

Whether the research presents risks to biological relatives or identifiable communities.

Indian biomedical research should be evaluated against the applicable legislation, regulatory requirements, institutional ethics procedures and relevant Indian Council of Medical Research ethical guidance.

An ethics approval is not a substitute for every legal permission, and a consent form does not automatically override statutory restrictions.

4. Important case laws: detailed legal analysis

The following decisions illustrate how courts balance personal rights, scientific innovation, public interests and commercial control.

1990

1. Moore v. Regents of the University of California

51 Cal. 3d 120 (Cal. 1990) — United States

The claimant's cells were used to develop a commercially valuable cell line without the disclosures he alleged were required. The California Supreme Court rejected conversion liability for the excised cells but permitted claims concerning breach of fiduciary duty and lack of informed consent to proceed.

Principle: A patient's consent and the researcher's disclosure obligations are distinct from ownership of a commercially developed cell line.

Justia Law+1

2013

2. Association for Molecular Pathology v. Myriad Genetics, Inc.

569 U.S. 576 (2013) — United States

The Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated, while cDNA may qualify as patent-eligible subject matter.

Principle: Patent law does not generally permit exclusive rights over naturally occurring genetic information merely because it has been discovered.

LII / Legal Information Institute+1

2017

3. Justice K.S. Puttaswamy (Retd.) v. Union of India

(2017) 10 SCC 1 — India

A nine-judge Constitution Bench recognized privacy as a fundamental right under the Indian Constitution.

Principle: Government collection and use of genetic information may raise constitutional privacy issues, particularly where personal autonomy, informational privacy or bodily integrity is implicated. The case was not specifically about genetic-material ownership.

1980

4. Diamond v. Chakrabarty

447 U.S. 303 (1980) — United States

The United States Supreme Court held that a genetically modified bacterium with markedly different characteristics could qualify as patentable subject matter.

Principle: A human-made biological invention may be patentable even though naturally occurring organisms and discoveries remain subject to important patentability limits. This decision must be read alongside Myriad and the particular patent statute applicable to a dispute.

Comparative legal lesson

These cases address different questions and should not be treated as interchangeable:

None of these decisions establishes an unrestricted right to exploit genetic material for commercial gain.

5. International legal framework

The legal restrictions on genetic-material exploitation arise from several overlapping international instruments.

The Nagoya Protocol is particularly important where research involves plant, animal or microbial genetic resources obtained from another country. It is not a universal ownership code for human DNA or every biological specimen.

Convention on Biological Diversity+1

6. Legal remedies for unlawful exploitation

Depending on the jurisdiction, the nature of the material and the harm suffered, potential remedies include:

Injunctions: To stop unauthorized use, disclosure or transfer where the legal requirements for relief are met.

Compensation or damages: For an established cause of action, such as negligence, breach of duty, breach of contract or a statutory violation.

Regulatory action: Investigation, penalties, suspension or other measures authorized by the applicable legislation.

Data-protection remedies: Complaints or proceedings concerning unlawful processing, security failures or unauthorized disclosure.

Intellectual-property remedies: Patent challenges, infringement proceedings or other patent-related relief where the relevant requirements are satisfied.

Benefit-sharing claims: Where an enforceable statutory or contractual entitlement exists.

Constitutional remedies: Against unlawful state action, subject to the applicable procedural and substantive requirements.

A claimant does not automatically receive a share of all profits generated from their genetic material. The available remedy depends on the legal basis of the claim and the evidence.

7. Practical examples

Scenario 1: A hospital sells a patient's tissue for commercial research

The central questions are whether the collection and subsequent use were lawfully authorized, whether material information was withheld, and whether privacy or research requirements were violated. Consent to surgery alone may not settle these issues.

Scenario 2: A biotechnology company patents a naturally occurring gene

Patentability must be examined under the applicable patent statute. Under Myriad, isolation alone was insufficient for natural DNA in the United States. India requires a separate assessment under its own statutory exclusions.

Scenario 3: A company commercializes a plant-derived medicine based on traditional knowledge

The company must assess access permissions, the applicability of Indian biodiversity legislation, the status of the knowledge and any benefit-sharing obligations. The mere fact that the knowledge is old does not resolve every question of lawful access or community entitlement.

Scenario 4: A researcher shares genetic data with an overseas institution

Relevant issues include consent, research authorization, confidentiality, applicable data-protection requirements, cross-border transfers and contractual restrictions. The fact that the data are scientifically valuable does not remove these obligations.

8. Conclusion

The legal limits on exploitation of genetic materials seek to reconcile scientific progress with human dignity, privacy, legitimate research, intellectual-property rights and equitable benefit-sharing.

The principal conclusions are:

Consent: Lawful collection does not necessarily authorize every later use.

Privacy: Genetic information may attract constitutional, statutory and confidentiality protections.

Ownership: Rights in an original sample, derived data and a resulting invention must be analyzed separately.

Patents: Naturally occurring genetic material is not automatically patentable merely because it has been discovered or isolated.

Biodiversity: Access to biological resources and associated traditional knowledge may trigger statutory permission and benefit-sharing requirements.

Accountability: Unauthorized exploitation may result in civil, regulatory, intellectual-property or constitutional proceedings, depending on the facts.

Ultimately, the law does not impose one universal prohibition on exploiting genetic materials. It establishes different restrictions according to the nature of the material, the source of access, the purpose of use, the rights affected and the applicable legal regime.

Legal note: This is a general academic explanation, not an opinion on a specific dispute. In an Indian matter, the exact statutory provisions, applicable commencement rules, consent documents and material-transfer agreements should be examined before drawing a definitive legal conclusion.